What the Researchers Found
The most severe form of pregnancy sickness now has ten genes attached to it, and six of them were not previously known.
Researchers at the Keck School of Medicine of USC and international collaborators conducted the largest genetic study of hyperemesis gravidarum to date, comparing 10,974 women with the condition against 461,461 controls across European, Asian, African and Latino ancestries. The results, published in Nature Genetics, identified ten associated genetic loci.
Four had been implicated in earlier work by the same group: GDF15, which produces a hormone that rises sharply in pregnancy; GFRAL, which produces the receptor for that hormone; and IGFBP7 and PGR, both involved in placental development. GDF15 remained by far the strongest association.
The six new ones are FSHB, TCF7L2, SLITRK1, SYN3, IGSF11 and CDH9. Together, the implicated genes touch pregnancy hormones, appetite regulation, nausea pathways, metabolism and brain plasticity.
Why This Matters
Hyperemesis gravidarum affects roughly 2% of pregnancies and produces nausea and vomiting severe enough that eating and drinking become extremely difficult. It can lead to dehydration, malnourishment and hospitalization, and it is a leading reason women are admitted to hospital in early pregnancy.
For most of medical history, it was treated as a psychological problem. Patients were told the vomiting reflected ambivalence about the pregnancy, anxiety, or an unwillingness to accept motherhood. That framing shaped how women were treated for decades and, by many patient accounts, still shapes some clinical encounters.
Genetic evidence does not by itself settle what causes an illness, but ten independent loci across four ancestry groups is difficult to reconcile with a purely psychological explanation. For a patient who has been told her severe vomiting is in her head, that is not an abstraction.
What This Study Adds and What Was Already Known
The biological case for hyperemesis gravidarum did not begin here, and it would overstate the finding to present this as the moment the question was resolved.
The same research group linked GDF15 and IGFBP7 to the condition in 2018 and expanded the genetic picture in subsequent work. Family studies established heritability well before that, including a substantially elevated risk among sisters of women with the condition.
What this study adds is scale and ancestral breadth. Earlier genome-wide analyses drew heavily on European ancestry cohorts. Including Asian, African and Latino ancestries makes the findings more likely to apply across populations, which matters in a condition where the patients most likely to be dismissed have often been those least represented in research.
The Genes That Point Somewhere Unexpected
Two findings stand out for where they might lead.
TCF7L2 is one of the strongest known genetic risk factors for type 2 diabetes and is also associated with gestational diabetes. Its appearance in a hyperemesis analysis connects severe pregnancy sickness to metabolic biology in a way that was not anticipated.
Downstream analyses found that GDF15 and TCF7L2 are expressed primarily in extravillous trophoblast, the placental cells that invade the uterine wall early in pregnancy. That locates part of the biology in the placenta rather than solely in the mother's brain or gut, which is consistent with the timing of the illness.
Other implicated genes, including SLITRK1 and SYN3, relate to brain plasticity and synaptic function, which may bear on why nausea signaling differs so markedly between individuals exposed to similar hormone levels.
What the Evidence Shows and What It Does Not
A genome-wide association study identifies statistical associations between genetic variants and a trait. It does not prove that any specific gene causes the condition, and it does not establish the mechanism.
The effect sizes in this kind of analysis are typically modest at the individual level. There is no genetic test that tells a woman whether she will develop hyperemesis gravidarum, and this study does not create one. Having a risk variant does not mean someone will be affected, and lacking one does not mean they are protected.
The study also cannot separate how much of the risk is maternal and how much is fetal, though the authors examined that question in downstream analyses. Case definitions for hyperemesis vary across the contributing datasets, which introduces some imprecision in who counted as a case.
No treatment follows directly from this paper. Nothing in it changes clinical management today.
The Treatment Path This Opens
The most practically interesting implication is not about diagnosis. It is about drugs that already exist.
Compounds targeting the GDF15 pathway are in clinical development for cancer cachexia, a condition involving appetite loss, weight loss, and nausea that shares features with hyperemesis gravidarum. Researchers have suggested that if such drugs prove safe, the shared pathway makes them a plausible candidate for hyperemesis.
That is a hypothesis with a real basis, not a promise. Testing any drug in pregnancy carries an additional layer of safety requirements, and no GDF15-targeting therapy has been trialed for this indication. Any timeline would be measured in years.
Who This Concerns
Women with a personal or family history of hyperemesis gravidarum face the highest recurrence risk, and knowing that a subsequent pregnancy may follow the same course allows for planning rather than surprise.
Clinicians are the other audience. Recognition matters because untreated hyperemesis leads to dehydration, electrolyte disturbance, weight loss, and, in prolonged cases, nutritional deficiencies that can cause serious neurological complications. Early and adequate treatment is the difference between a difficult pregnancy and a dangerous one.
Warning Signs That Need Medical Care
Nausea and vomiting affect most pregnancies and are usually manageable. The pattern that requires evaluation is different.
Inability to keep down fluids for 24 hours, weight loss in early pregnancy, urinating far less than usual or producing very dark urine, dizziness on standing, a racing heart, or vomiting that continues past the first trimester all warrant contacting an obstetric provider rather than waiting.
Confusion, severe weakness, vision changes, or difficulty walking in someone who has been vomiting persistently is a medical emergency and can indicate a thiamine deficiency that requires urgent treatment.
What You Can Do Now
Anyone experiencing severe pregnancy nausea should raise it with an obstetric provider as a medical problem rather than something to endure. Effective treatments exist, including prescription antiemetics, intravenous fluids and nutritional support, and guidelines support escalating treatment when first-line options fail.
Patients who feel their symptoms are being minimized are entitled to ask directly for a treatment plan, to request a referral to a maternal-fetal medicine specialist, or to seek a second opinion. Documenting weight, fluid intake, and vomiting frequency before an appointment makes the severity harder to dismiss.
No one should start or stop a medication based on this study, and no one should conclude from it that their symptoms are genetically determined and therefore untreatable. The opposite is closer to the point.
What Happens Next
The research team and others will work to move from association to mechanism, determining how these genes influence nausea and vomiting and which are maternal versus fetal in origin. Whether GDF15-pathway drugs under development for other conditions could be safely tested in pregnancy is the question with the clearest treatment implications. MedicalDaily will report if clinical trials for hyperemesis gravidarum are registered.
The Bottom Line
The confirmed finding is ten genetic loci associated with hyperemesis gravidarum, six newly identified, across nearly half a million women of multiple ancestries. The people it concerns most are women with a personal or family history of severe pregnancy sickness. The useful action is treating severe symptoms as a medical condition that warrants escalating care. The central uncertainty is mechanism, and no treatment follows from this study yet.
